PT2424495T - Tratamento de neuropatia ótica hereditária de leber e atrofia ótica dominante com quinonas de tocotrienol - Google Patents
Tratamento de neuropatia ótica hereditária de leber e atrofia ótica dominante com quinonas de tocotrienol Download PDFInfo
- Publication number
- PT2424495T PT2424495T PT107156507T PT10715650T PT2424495T PT 2424495 T PT2424495 T PT 2424495T PT 107156507 T PT107156507 T PT 107156507T PT 10715650 T PT10715650 T PT 10715650T PT 2424495 T PT2424495 T PT 2424495T
- Authority
- PT
- Portugal
- Prior art keywords
- tocotrienol
- tocotrienol quinone
- preparation
- weight
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21479509P | 2009-04-28 | 2009-04-28 | |
| US31873310P | 2010-03-29 | 2010-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2424495T true PT2424495T (pt) | 2018-03-13 |
Family
ID=42244195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT107156507T PT2424495T (pt) | 2009-04-28 | 2010-04-27 | Tratamento de neuropatia ótica hereditária de leber e atrofia ótica dominante com quinonas de tocotrienol |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20100273894A1 (https=) |
| EP (2) | EP3332766A1 (https=) |
| JP (3) | JP2012525399A (https=) |
| BR (1) | BRPI1013376A8 (https=) |
| CA (1) | CA2777479C (https=) |
| DK (1) | DK2424495T3 (https=) |
| EA (1) | EA031126B1 (https=) |
| ES (1) | ES2662051T3 (https=) |
| HU (1) | HUE037574T2 (https=) |
| MX (1) | MX336800B (https=) |
| NO (1) | NO2424495T3 (https=) |
| PL (1) | PL2424495T3 (https=) |
| PT (1) | PT2424495T (https=) |
| SI (1) | SI2424495T1 (https=) |
| WO (1) | WO2010126911A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005033093A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| ES2619303T3 (es) * | 2005-06-01 | 2017-06-26 | Edison Pharmaceuticals, Inc. | Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos |
| WO2007100652A2 (en) | 2006-02-22 | 2007-09-07 | Edison Pharmaceuticals, Inc. | Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| EA038941B1 (ru) | 2007-11-06 | 2021-11-12 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ |
| US8952071B2 (en) * | 2008-01-08 | 2015-02-10 | Edison Pharmaceuticals, Inc. | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| JP5798481B2 (ja) * | 2008-06-25 | 2015-10-21 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス疾患を治療するための２−ヘテロシクリルアミノアルキル−（ｐ−キノン）誘導体 |
| MX363223B (es) | 2008-09-10 | 2019-03-15 | Bioelectron Tech Corp | Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox. |
| EP2362726B1 (en) | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| ES2553557T3 (es) | 2008-10-28 | 2015-12-10 | Edison Pharmaceuticals, Inc. | Proceso para la producción de alfa-tocotrienol y derivados |
| CA2777479C (en) | 2009-04-28 | 2017-10-17 | Ptc Therapeutics, Inc. | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones |
| NO2470168T3 (https=) * | 2009-08-26 | 2018-06-30 | ||
| US20110172312A1 (en) * | 2009-12-31 | 2011-07-14 | Miller Guy M | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| EP2642991A1 (en) | 2010-11-22 | 2013-10-02 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Therapeutical method for the treatment of the leber optic |
| WO2012174286A1 (en) * | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| ES2795798T3 (es) * | 2011-07-06 | 2020-11-24 | Ptc Therapeutics Inc | Tratamiento de aciduria metilmalónica, aciduria isovalérica, y otras acidurias orgánicas con tocotrienol quinonas |
| EP2734512B1 (en) | 2011-07-19 | 2019-11-20 | Bioelectron Technology Corporation | Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
| JP6238977B2 (ja) | 2012-06-29 | 2017-11-29 | ラオフ・レキク | 視神経症または先天性視神経萎縮を治療するためのアンギオテンシン変換酵素阻害薬 |
| CA2883882A1 (en) | 2012-09-07 | 2014-03-13 | Ptc Therapeutics, Inc. | Benzoquinone derivatives for treating oxidative stress disorders |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US10189830B2 (en) | 2013-03-15 | 2019-01-29 | Bioelectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| WO2015103577A1 (en) * | 2014-01-06 | 2015-07-09 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating dominant optic atrophy |
| DK3233786T3 (da) | 2014-12-16 | 2022-05-09 | Ptc Therapeutics Inc | Polymorfe og amorfe former af (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6- dioxocyclohexa-1,4-dienyl)butanamid |
| US11337980B2 (en) | 2015-06-05 | 2022-05-24 | Fundació Hospital Universitari Vall D'hebron-Institut De Recerca | Treatment of mitochondrial diseases |
| WO2017106786A1 (en) | 2015-12-16 | 2017-06-22 | Bioelectron Technology Corporation | Improved methods for enriching alpha-tocotrienol from mixed tocol compositions |
| US10703701B2 (en) | 2015-12-17 | 2020-07-07 | Ptc Therapeutics, Inc. | Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
| CN112888419A (zh) * | 2018-10-11 | 2021-06-01 | 安布里亚制药公司 | 用于治疗和预防Leber遗传性视神经病变的组合物和方法 |
| RU2704013C1 (ru) * | 2019-04-18 | 2019-10-23 | ФГБНУ "НИИ глазных болезней" | Способ коррекции окислительного стресса при наследственной оптической нейропатии Лебера |
| CN112385783B (zh) | 2020-10-10 | 2022-07-05 | 南京农业大学 | 一种控制炭烤肉中多环芳烃含量的烤制方法 |
| WO2024259130A1 (en) * | 2023-06-16 | 2024-12-19 | Ptc Therapeutics, Inc. | Methods for increasing vatiquinone plasma exposure with food |
Family Cites Families (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4875564A (https=) | 1972-01-08 | 1973-10-11 | ||
| JPS4988862A (https=) | 1972-12-29 | 1974-08-24 | ||
| US4883658A (en) | 1986-04-28 | 1989-11-28 | Holly Frank J | Ophthalmic solution for treatment of dry-eye syndrome |
| US4804539A (en) | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
| JPH0788376B2 (ja) | 1986-09-02 | 1995-09-27 | エーザイ株式会社 | 光学活性α−トコトリエノ−ルの製造方法 |
| US5278151A (en) | 1987-04-02 | 1994-01-11 | Ocular Research Of Boston, Inc. | Dry eye treatment solution |
| US4914088A (en) | 1987-04-02 | 1990-04-03 | Thomas Glonek | Dry eye treatment solution and method |
| JP2685785B2 (ja) | 1988-03-11 | 1997-12-03 | エーザイ株式会社 | 光学活性α−トコトリエノールの製造方法 |
| JPH029875A (ja) | 1988-03-16 | 1990-01-12 | Bio Ind Kyokai | トコフェロール及びトコトリエノールの製造方法 |
| US5075104A (en) | 1989-03-31 | 1991-12-24 | Alcon Laboratories, Inc. | Ophthalmic carboxy vinyl polymer gel for dry eye syndrome |
| US5157132A (en) | 1990-05-18 | 1992-10-20 | Carotech Associates | Integrated process for recovery of carotenoids and tocotrienols from oil |
| ZA912797B (en) | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
| EP0459148B1 (en) | 1990-05-29 | 1996-01-03 | Ocular Research Of Boston Inc. | Dry eye treatment composition |
| ZA927277B (en) | 1991-10-02 | 1993-05-19 | Boston Ocular Res | Dry eye treatment process and solution. |
| SG48108A1 (en) | 1991-11-22 | 1998-04-17 | Lipogenenics Inc | Tocotrienols and tocotrienol-like compounds and methods for their use |
| US5318993A (en) * | 1993-04-16 | 1994-06-07 | Bristol-Myers Squibb Company | Antihyperlipidemic benzoquinones |
| CN1129400A (zh) | 1994-05-06 | 1996-08-21 | 阿尔康实验室公司 | 维生素e生育酚衍生物在眼科组合物中的应用 |
| EP0801564B1 (en) | 1994-12-28 | 2002-03-27 | Janssen Pharmaceutica N.V. | Use of nebivolol as an anti-atherogenic |
| US6232060B1 (en) | 1996-01-19 | 2001-05-15 | Galileo Laboratories, Inc. | Assay system for anti-stress agents |
| US5801159A (en) | 1996-02-23 | 1998-09-01 | Galileo Laboratories, Inc. | Method and composition for inhibiting cellular irreversible changes due to stress |
| EP1051412B1 (en) | 1998-01-29 | 2003-09-24 | Eastman Chemical Company | Methods for separating a tocotrienol from a tocol-containing mixture and compositions thereof |
| WO2000078296A2 (en) | 1999-06-17 | 2000-12-28 | Basf Aktiengesellschaft | Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders |
| US6395915B1 (en) | 1999-09-10 | 2002-05-28 | Technikrom, Inc. | Method for producing purified tocotrienols and tocopherols using liquid chromatography |
| US6426362B1 (en) | 1999-10-08 | 2002-07-30 | Galileo Laboratories, Inc. | Formulations of tocopherols and methods of making and using them |
| US6528042B1 (en) | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
| MY127451A (en) | 1999-11-04 | 2006-12-29 | Malaysian Palm Oil Board | A method of chromatographic isolation for vitamin e isomers |
| DE10034233A1 (de) | 2000-07-14 | 2002-01-24 | Basf Ag | Tocotrienolchinon-Cyclisierungsprodukte |
| GB0023555D0 (en) * | 2000-09-26 | 2000-11-08 | Inst Of Ophthalmology | Improvements in and relating to treatments for eye disease |
| AU2002239748A1 (en) | 2000-12-15 | 2002-06-24 | Galileo Laboratories, Inc. | Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia |
| US7034054B2 (en) | 2000-12-15 | 2006-04-25 | Galileo Pharmaceuticals, Inc. | Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols |
| US6838104B2 (en) | 2000-12-20 | 2005-01-04 | Archer Daniels Midland Company | Process for the production of tocotrienols |
| US6608196B2 (en) | 2001-05-03 | 2003-08-19 | Galileo Pharmaceuticals, Inc. | Process for solid supported synthesis of pyruvate-derived compounds |
| CA2456743A1 (en) | 2001-08-21 | 2003-02-27 | Galileo Pharmaceuticals, Inc. | Tocopherol enriched compositions and amelioration of inflammatory symptoms |
| AU2002352726A1 (en) | 2001-11-15 | 2003-06-10 | Galileo Laboratories, Inc. | Formulations and methods for treatment or amelioration of inflammatory conditions |
| US6667330B2 (en) | 2002-01-31 | 2003-12-23 | Galileo Pharmaceuticals, Inc. | Furanone derivatives |
| US6653346B1 (en) | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
| US7078541B2 (en) | 2002-02-07 | 2006-07-18 | Galileo Pharmaceuticals, Inc. | Benzofuran derivatives |
| EP1378753B1 (en) | 2002-07-01 | 2006-05-31 | Santhera Pharmaceuticals (Schweiz) GmbH | A screening method and compounds for treating Friedreich Ataxia |
| AU2003287250B9 (en) | 2002-10-30 | 2010-01-28 | Ptc Therapeutics, Inc. | Identifying therapeutic compounds based on their physical-chemical properties |
| US7015243B2 (en) * | 2003-08-28 | 2006-03-21 | Allergan, Inc. | Cyclohexyl prostaglandin analogs as EP4-receptor agonists |
| WO2005033093A1 (en) | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
| WO2005032478A2 (en) * | 2003-10-01 | 2005-04-14 | Yasoo Health, Inc. | Treatment for diabetic microvascular and macrovascular complications |
| WO2005035490A2 (en) | 2003-10-10 | 2005-04-21 | Yasoo Health, Inc. | PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS |
| JP5129563B2 (ja) | 2004-03-18 | 2013-01-30 | ラスク・インテレクチュアル・リザーブ・アクチェンゲゼルシャフト | 視神経症に対する感受性を診断または予測するための方法 |
| EP1611879B1 (en) | 2004-07-02 | 2009-08-12 | Novagali Pharma SA | Use of emulsions for intra- and periocular injection |
| US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
| ES2532997T3 (es) | 2005-04-22 | 2015-04-06 | Elizabeth Stuart | Uso de tocotrienoles de vitamina E para la inhibición del patógeno intracelular obligado Chlamydia |
| ES2619303T3 (es) | 2005-06-01 | 2017-06-26 | Edison Pharmaceuticals, Inc. | Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos |
| SI1933821T1 (sl) | 2005-09-15 | 2020-11-30 | Ptc Therapeutics, Inc. | Repne variante redoks-aktivnih terapevtikov za zdravljenje mitohondrijskih bolezni in drugih bolezni ter modulacijo energijskih biooznačevalcev |
| CA2850858A1 (en) | 2005-09-16 | 2007-04-05 | Allergan, Inc. | Compositions and methods for the intraocular transport of therapeutic agents |
| WO2007100652A2 (en) | 2006-02-22 | 2007-09-07 | Edison Pharmaceuticals, Inc. | Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers |
| WO2008086025A2 (en) | 2007-01-10 | 2008-07-17 | Edison Pharmaceuticals, Inc. | Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity |
| WO2008157747A1 (en) | 2007-06-21 | 2008-12-24 | The Jackson Laboratory | Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders |
| EP2170374A2 (en) | 2007-07-03 | 2010-04-07 | Andreas Reichert | Method for treating diseases related to mitochondrial dysfunction |
| ES2507078T3 (es) | 2007-08-16 | 2014-10-14 | Santen Pharmaceutical Co., Ltd | Formulaciones de rapamicina para tratamiento de la degeneración macular relacionada con la edad |
| US8075909B2 (en) | 2007-09-04 | 2011-12-13 | University Of Florida Research Foundation, Incorporated | Contact lens based bioactive agent delivery system |
| EA038941B1 (ru) | 2007-11-06 | 2021-11-12 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | ПРОИЗВОДНЫЕ 4-(п-ХИНОНИЛ)-2-ГИДРОКСИБУТАНАМИДА ДЛЯ ЛЕЧЕНИЯ МИТОХОНДРИАЛЬНЫХ ЗАБОЛЕВАНИЙ |
| EP2242506A4 (en) | 2008-01-07 | 2011-12-28 | Janssen Biotech Inc | METHOD FOR THE TREATMENT OF ERYTHROPOIETIN HYPORESPONSE ANIMALS |
| US8952071B2 (en) | 2008-01-08 | 2015-02-10 | Edison Pharmaceuticals, Inc. | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
| EP2262519A4 (en) | 2008-03-05 | 2011-03-23 | Edison Pharmaceuticals Inc | TREATMENT OF HEARING AND BALANCING DISORDERS WITH REDOXACTIVE THERAPEUTICS |
| WO2009111576A2 (en) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| US20110142834A1 (en) | 2008-05-15 | 2011-06-16 | Edison Pharmaceuticals, Inc. | Treatment of hearing and balance impairments using compounds having erythropoietin activity |
| US20090291092A1 (en) | 2008-05-22 | 2009-11-26 | Miller Guy M | Treatment of mitochondrial diseases with an erythropoietin mimetic |
| JP5798481B2 (ja) | 2008-06-25 | 2015-10-21 | エジソン ファーマシューティカルズ， インコーポレイテッド | 酸化ストレス疾患を治療するための２−ヘテロシクリルアミノアルキル−（ｐ−キノン）誘導体 |
| WO2010005989A1 (en) | 2008-07-09 | 2010-01-14 | Edison Pharmaceuticals, Inc. | Dermatological compositions with anti-aging and skin even-toning properties |
| US20100029784A1 (en) | 2008-07-30 | 2010-02-04 | Hinman Andrew W | Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties |
| MX363223B (es) | 2008-09-10 | 2019-03-15 | Bioelectron Tech Corp | Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox. |
| CN107468648A (zh) | 2008-10-09 | 2017-12-15 | 拉姆斯科股份有限公司 | 治疗干眼综合征的组合物和方法 |
| EP2362726B1 (en) | 2008-10-14 | 2018-08-08 | Bioelectron Technology Corporation | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
| ES2553557T3 (es) | 2008-10-28 | 2015-12-10 | Edison Pharmaceuticals, Inc. | Proceso para la producción de alfa-tocotrienol y derivados |
| EA201101576A1 (ru) | 2009-04-28 | 2012-04-30 | Эдисон Фармасьютикалз, Инк. | Лекарственная форма токотриенол хинонов для лечения офтальмических (глазных) заболеваний |
| US20120136048A1 (en) | 2009-04-28 | 2012-05-31 | Miller Guy M | Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases |
| CA2777479C (en) | 2009-04-28 | 2017-10-17 | Ptc Therapeutics, Inc. | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones |
| EP2445519A4 (en) | 2009-06-25 | 2012-12-26 | Ampere Life Sciences Inc | TREATMENT OF PERVASIVE DEVELOPMENT DISORDERS USING TOCOTRIENOLS OR TOCOTRIENOLS ENRICHED EXTRACTS |
| NO2470168T3 (https=) | 2009-08-26 | 2018-06-30 | ||
| WO2011041452A2 (en) | 2009-10-01 | 2011-04-07 | Ampere Life Sciences, Inc. | Mouse model for identifying compounds for the treatment of oxidative stress |
| US20110172312A1 (en) | 2009-12-31 | 2011-07-14 | Miller Guy M | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| WO2011113018A1 (en) | 2010-03-12 | 2011-09-15 | Ampere Life Sciences, Inc. | Measurement and control of biological time |
| CA2795726A1 (en) | 2010-04-06 | 2011-10-13 | Edison Pharmaceuticals, Inc. | Treatment of ataxia telangiectasia |
| JP5902673B2 (ja) | 2010-04-27 | 2016-04-13 | エジソン ファーマシューティカルズ， インコーポレイテッド | 眼疾患の処置のためのキノンの製剤 |
| US20120101169A1 (en) | 2010-07-14 | 2012-04-26 | Penwest Pharmaceuticals Co. | Methods of providing anticoagulation effects in subjects |
| SG187744A1 (en) | 2010-08-06 | 2013-03-28 | Edison Pharmaceuticals Inc | Treatment of mitochondrial diseases with naphthoquinones |
| WO2012019032A1 (en) | 2010-08-06 | 2012-02-09 | Ampere Life Sciences, Inc. | Treatment of mitochondrial diseases with vitamin k |
| US20120295985A1 (en) | 2010-11-19 | 2012-11-22 | Miller Guy M | Methods for improving blood glucose control |
| WO2012154613A1 (en) | 2011-05-06 | 2012-11-15 | Edison Pharmaceuticals, Inc. | Improved process for the preparation of d-alpha-tocotrienol from natural extracts |
| WO2012170773A1 (en) | 2011-06-08 | 2012-12-13 | Edison Pharmaceuticals, Inc. | Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones |
| WO2012174286A1 (en) | 2011-06-14 | 2012-12-20 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| ES2795798T3 (es) | 2011-07-06 | 2020-11-24 | Ptc Therapeutics Inc | Tratamiento de aciduria metilmalónica, aciduria isovalérica, y otras acidurias orgánicas con tocotrienol quinonas |
| WO2013006736A1 (en) | 2011-07-06 | 2013-01-10 | Edison Pharmaceuticals, Inc | Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones |
| EP2734512B1 (en) | 2011-07-19 | 2019-11-20 | Bioelectron Technology Corporation | Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
| CA2883882A1 (en) | 2012-09-07 | 2014-03-13 | Ptc Therapeutics, Inc. | Benzoquinone derivatives for treating oxidative stress disorders |
| CN105142603B (zh) | 2013-03-08 | 2018-10-19 | 荷兰联合利华有限公司 | 用于皮肤病用途的间苯二酚化合物 |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| US10189830B2 (en) | 2013-03-15 | 2019-01-29 | Bioelectron Technology Corporation | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders |
| US20140275045A1 (en) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| EP3004071A1 (en) | 2013-05-31 | 2016-04-13 | Edison Pharmaceuticals, Inc. | Carboxylic acid derivatives for treatment of oxidative stress disorders |
-
2010
- 2010-04-27 CA CA2777479A patent/CA2777479C/en not_active Expired - Fee Related
- 2010-04-27 JP JP2012508609A patent/JP2012525399A/ja not_active Withdrawn
- 2010-04-27 ES ES10715650.7T patent/ES2662051T3/es active Active
- 2010-04-27 MX MX2011011309A patent/MX336800B/es active IP Right Grant
- 2010-04-27 PL PL10715650T patent/PL2424495T3/pl unknown
- 2010-04-27 DK DK10715650.7T patent/DK2424495T3/en active
- 2010-04-27 NO NO10715650A patent/NO2424495T3/no unknown
- 2010-04-27 PT PT107156507T patent/PT2424495T/pt unknown
- 2010-04-27 SI SI201031630T patent/SI2424495T1/en unknown
- 2010-04-27 US US12/768,565 patent/US20100273894A1/en not_active Abandoned
- 2010-04-27 EP EP18151731.9A patent/EP3332766A1/en not_active Withdrawn
- 2010-04-27 WO PCT/US2010/032624 patent/WO2010126911A1/en not_active Ceased
- 2010-04-27 HU HUE10715650A patent/HUE037574T2/hu unknown
- 2010-04-27 EP EP10715650.7A patent/EP2424495B1/en not_active Not-in-force
- 2010-04-27 EA EA201101575A patent/EA031126B1/ru not_active IP Right Cessation
- 2010-04-27 BR BRPI1013376A patent/BRPI1013376A8/pt not_active Application Discontinuation
-
2013
- 2013-04-09 US US13/859,592 patent/US9370496B2/en active Active
-
2014
- 2014-11-07 JP JP2014226669A patent/JP2015028084A/ja not_active Withdrawn
-
2016
- 2016-06-09 US US15/178,423 patent/US10195161B2/en not_active Expired - Fee Related
- 2016-09-21 JP JP2016183749A patent/JP2016216506A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10195161B2 (en) | 2019-02-05 |
| JP2012525399A (ja) | 2012-10-22 |
| US20100273894A1 (en) | 2010-10-28 |
| PL2424495T3 (pl) | 2018-06-29 |
| EP2424495B1 (en) | 2018-01-17 |
| SI2424495T1 (en) | 2018-04-30 |
| US20140039065A1 (en) | 2014-02-06 |
| ES2662051T3 (es) | 2018-04-05 |
| US20170119695A1 (en) | 2017-05-04 |
| DK2424495T3 (en) | 2018-04-30 |
| HUE037574T2 (hu) | 2018-09-28 |
| BRPI1013376A8 (pt) | 2018-01-09 |
| JP2015028084A (ja) | 2015-02-12 |
| MX2011011309A (es) | 2011-11-18 |
| JP2016216506A (ja) | 2016-12-22 |
| EP2424495A1 (en) | 2012-03-07 |
| EP3332766A1 (en) | 2018-06-13 |
| CA2777479A1 (en) | 2010-11-04 |
| US9370496B2 (en) | 2016-06-21 |
| EA201101575A1 (ru) | 2012-04-30 |
| CA2777479C (en) | 2017-10-17 |
| MX336800B (es) | 2016-02-02 |
| BRPI1013376A2 (pt) | 2017-03-21 |
| EA031126B1 (ru) | 2018-11-30 |
| WO2010126911A1 (en) | 2010-11-04 |
| NO2424495T3 (https=) | 2018-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2424495T (pt) | Tratamento de neuropatia ótica hereditária de leber e atrofia ótica dominante com quinonas de tocotrienol | |
| AU2011245384B9 (en) | Formulations of quinones for the treatment of ophthalmic diseases | |
| AU2011245384C1 (en) | Formulations of quinones for the treatment of ophthalmic diseases | |
| US20100273892A1 (en) | Formulations of tocotrienol quinones for the treatment of ophthalmic diseases | |
| US20210145769A1 (en) | Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones | |
| US20130143966A1 (en) | Methods of treatment using sterculic acid | |
| HK1168028B (en) | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones | |
| HK1168028A (en) | Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones |